J&J's Gorsky stands by Remicade longevity as biosimilar impact hits Europe
This article was originally published in Scrip
Executive Summary
Johnson & Johnson expects the biosimilar market to behave quite differently than generics, said CEO Alex Gorsky, even as international sales of Remicade (infliximab) fell 20% in the second quarter, though largely due to currency.